SVBI Business Summary

SciVision Biotech Inc. (SVBI) operates a vertically integrated business model centered on the research, development, and manufacturing of medical-grade hyaluronic acid (HA) products using its proprietary cross-linking technology platform. The company generates the majority of its revenue through the sale of high-margin medical devices across four primary segments: Orthopedics (synovial fluid supplements like Hyaflex), Medical Aesthetics (facial dermal fillers), Surgical (absorbable adhesion barriers), and Urology (intravesical instillation products). SVBI also maintains a secondary revenue stream from HA-based skincare and cosmetics. As of March 2026, the company continues to expand its global footprint, with significant market penetration in Asia and Europe. Within the Taiwan medical device sector, SVBI competes directly with firms such as Pacific Hospital Supply (4126.TW), Vizionfocus (4771.TW), and ICARES Medicus (6612.TW), positioning itself as a specialized leader in high-purity HA applications for minimally invasive clinical procedures. SVBI was founded in 2001 by the Han brothers, who combine technical engineering and life sciences expertise to lead the firm. Chairman Kai Cheng Han, a graduate of the Whampoa Military Academy with an electrical engineering background, oversees strategic direction and corporate governance, while CEO and General Manager Tai Xian Han (Han Tai-Hsien) leverages his biological sciences pedigree from National Sun Yat-sen University to spearhead R&D and product innovation. The executive team is supported by Deputy General Manager and CFO Ru Ling Guo, who manages the company’s robust financial operations and investor relations. The board of directors is notable for its inclusion of high-profile medical experts, such as independent director Chao-Long Chen, a world-renowned liver transplant pioneer, and institutional backing from investors like Maxima Capital Management, reflecting the company's strong reputation within the regional biotechnology ecosystem.